Slingshot members are tracking this event:
FDA Completes Post Action Meeting with Lipocine (LPCN) Regarding LPCN 1021 in Testosterone Replacement Therapy
Slingshot Insights Explained
Oct 17, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Fda, Post Action Meeting, Lpcn 1021, Testosterone Replacement Therapy, Hypogonadism